Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

On 4 June 2020, after a week of increasing scientific concern and scrutiny, first The Lancet, then a little over an hour later the New England Journal of Medicine, retracted studies that were based on inaccessible data, provided by the Surgisphere corporation. The studies have been extremely damaging to chloroquine and hydroxychloroquine COVID-19 clinical trials around the globe. Here is MORU’s statement in response to these events.

The Lancet paper by Mehra et al. (May 22) which claimed that hydroxychloroquine increased mortality in COVID-19 and caused arrhythmias was retracted yesterday.

So was its predecessor in the New England Journal of Medicine.

Both studies were based on inaccessible, and therefore unverifiable data, provided by the Surgisphere corporation.

Unfortunately, the Lancet paper, the subsequent media coverage, and the reaction by some regulatory authorities (notably the UK regulator MHRA) and WHO have all been extremely damaging to the chloroquine and hydroxychloroquine COVID-19 clinical trials. Some studies, including our COPCOV prophylaxis study, which aims to see if these drugs at lower doses may prevent illness (which has yet to be answered, and may still be the case even if these drugs don’t work in treatment), have still not been given permission to restart. All the scientific evidence was put before the MHRA shortly after their decision to issue a notice stating they were minded to suspend the trial, and suggesting we stop enrolment, two weeks ago.

Many important questions will need to be answered in the coming weeks and months, but we would like to use this unfortunate opportunity to make two relevant recommendations which we believe are in the public interest.

  1. Medical and scientific journals should not accept papers based on inaccessible data
  2. Regulatory authorities and other agencies responding to such reports should satisfy themselves of the veracity and applicability of published data and the correctness of analyses before they act

Similar stories

Arjen Dondorp, Peter Horby and Rose McGready elected Academy of Medical Sciences Fellows

Awards & Appointments MORU Bangkok SMRU

"Although it is hard to look beyond the pandemic right now," says President of the Academy of Medical Sciences Professor Dame Anne Johnson, "I want to stress how important it is that the Academy Fellowship represents the widest diversity of biomedical and health sciences. The greatest health advances rely on the findings of many types of research, and on multidisciplinary teams and cross-sector and global collaboration."

Pint of Science Thailand is back

MORU Bangkok Public Engagement

Live and on-line from Bangkok! Be ready for Thursday 13th May, when Pint of Science Thailand will stream live from Bangkok. Join us via Facebook, YouTube or right here from the Pint of Science Thailand website as we journey from bacterial infections to viruses, discover how clinical trials work, and how scientific development is seen in the eyes of the law!

Innovative strategies for engaging communities with malaria research

MORU Bangkok Public Engagement

For World Malaria Day 2021, F1000 Research Blog spoke to Professor Phaik Yeong Cheah about her research focussed on drama and arts-based community engagement for malaria research, published with Wellcome Open Research.

New project’s child-appropriate primaquine doses could have significant impact on global burden of malaria

MORU Bangkok

On Sunday 25 April, World Malaria Day, the Developing Paediatric Primaquine (DPP) project will launch its website. DPP will produce children-appropriate primaquine doses that could both cut malaria deaths in vulnerable African children by blocking transmission of P. falciparum malaria and reduce P. vivax malaria more widely.

Researchers call for access to Ivermectin for young children

MORU Bangkok Publication Research

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

New report highlights growing concern of vaccine falsification

MORU Bangkok

The Medicine Quality Research Group has published a new Medical Product Quality Report focussing on increasing issues around substandard and falsified (SF) COVID-19 vaccines. With the implementation of the key innovations of COVID-19 vaccines, there have been growing numbers of reports of SF vaccines in the public domain. Given the vital role they will play in ending the pandemic and protecting the global population but severe issues with equitable access, SF vaccines are highly likely to be a growing problem.